A healthcare company trying to launch a new headache curing drug. Should or shouldn't they invest when they already have a general painkiller in the market
Back to overview
20
How would I approach this? Possible Framework?
2
4.7k
Be the first to answer!
Nobody has responded to this question yet.
Top answer
McKinsey / Accenture Alum / Got all BIG3 offers / Harvard Business School
Hi,
Hi,
I recommend starting with clarifying the objective - Which metrics you need to achieve with the product? Most probably it will be ROI.
I would also clarify whether it's our painkiller on the market or the product of the competitors since competition and cannibalization are the two different cases. Then I will follow up with the structure:
Analyze our product:
- The value proposition of a product compared to the painkiller
- Different use cases of a product compared to the painkiller
- Unit economics (Current unit costs and costs in relation to scale, Investments, ROI targets, Competitor / substitutes pricing)
- Key capabilities to compete (Patent, distribution, etc)
Analyze the market:
- Size and growth rates of the painkiller market
- Size and growth rate of headache drugs
- Regulation - are they both OTC? Prescribed? Is it different by geography?
Analyze the competitors:
- Market shares, growth rates, profits
- Product (Value proposition)
- Unit economics (Value proposition vs. price vs. costs)
- Key capabilities (Distribution, supply, assets, knowledge, etc)
investment decision:
- Costs, benefits, and investments
- ROI
- Risks
Best!
0 comments
Sidi
on Jun 05, 2018
Coach
McKinsey Senior EM & BCG Consultant | Interviewer at McK & BCG for 7 years | Coached 500+ candidates secure MBB offers
Hi Anonymous,
the new drug should be launched if the net value associated with this move exceeds the investment cost over the client's target investment horizon. Morover, Risk needs to be manageable.
So you have 4 buckets to investigate:
- Net value (expected profits of new drug + impact on profits of current painkiller (potential cannibalization!))
- Investment Horizon
- Investment need for launch of the new drug
- Wider risks associated with the new drug (regulation? competitive responses? consumer sentiment?...)
Cheers, Sidi
Similar Questions
Most Popular Posts
5 days left - McKinsey Interviews
23
on Sep 05, 2026
Europe
7
400+
Top answer by
Franco
Coach
Ex BCG Principal & Global Interviewer (10+ Years) | 100+ MBB Offers | 95% Success Rate
7 Answers
400+ Views
+4
When is Mckinsey sending Solve Invitations for rolling basis applications?
11
on Sep 05, 2026
Europe
3
300+
Top answer by
Ian
Coach
Ex-BCG | NYU Stern | MBB, Tech, & Strategy Coach | 5,000+ Sessions | 500+ Offers | 1,000+ Candidates | 100+ Countries
3 Answers
300+ Views
CL reapplication structure
18
on Sep 05, 2026
Middle East
4
300+
Top answer by
Ian
Coach
Ex-BCG | NYU Stern | MBB, Tech, & Strategy Coach | 5,000+ Sessions | 500+ Offers | 1,000+ Candidates | 100+ Countries
4 Answers
300+ Views
+1
MBB ban period
15
on Sep 05, 2026
Middle East
4
300+
Top answer by
Franco
Coach
Ex BCG Principal & Global Interviewer (10+ Years) | 100+ MBB Offers | 95% Success Rate
4 Answers
300+ Views
+1
Bain - Private Equity Consutling
12
on Sep 07, 2026
DACH
8
200+
Top answer by
Franco
Coach
Ex BCG Principal & Global Interviewer (10+ Years) | 100+ MBB Offers | 95% Success Rate
8 Answers
200+ Views
+5